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Abstract
Recently, the prevalence of Fasciola hepatica in some areas has increased considerably
and the availability of a vaccine to protect livestock from infection would represent a major
advance in tools available for controlling this disease. To date, most vaccine-target dis-
covery research on this parasite has concentrated on proteomic and transcriptomic
approaches whereas little work has been carried out on glycosylation. As the F. hepatica
tegument (Teg) may contain glycans potentially relevant to vaccine development and the
Newly Excysted Juvenile (NEJ) is the first lifecycle stage in contact with the definitive
host, our work has focused on assessing the glycosylation of the NEJTeg and identifying
the NEJTeg glycoprotein repertoire. After in vitro excystation, NEJ were fixed and NEJTeg
was extracted. Matrix-assisted laser desorption ionisation-time of flight-mass spectrome-
try (MALDI-TOF-MS) analysis of released N-glycans revealed that oligomannose and
core-fucosylated truncated N-glycans were the most dominant glycan types. By lectin
binding studies these glycans were identified mainly on the NEJ surface, together with the
oral and ventral suckers. NEJTeg glycoproteins were affinity purified after targeted bioti-
nylation of the glycans and identified using liquid chromatography and tandem mass spec-
trometry (LC-MS/MS). From the total set of proteins previously identified in NEJTeg,
eighteen were also detected in the glycosylated fraction, including the F. hepatica Cathep-
sin B3 (FhCB3) and two of the Cathepsin L3 (FhCL3) proteins, among others. To confirm
glycosylation of cathepsins, analysis at the glycopeptide level by LC-ESI-ion-trap-MS/MS
with collision-induced dissociation (CID) and electron-transfer dissociation (ETD) was car-
ried out. We established that cathepsin B1 (FhCB1) on position N80, and FhCL3
(BN1106_s10139B000014, scaffold10139) on position N153, carry unusual
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paucimannosidic Man2GlcNAc2 glycans. To our knowledge, this is the first description of
F. hepatica NEJ glycosylation and the first report of N-glycosylation of F. hepatica cathep-
sins. The significance of these findings for immunological studies and vaccine develop-
ment is discussed.
Author Summary
Fasciola hepatica is a parasite responsible for the zoonotic disease fasciolosis, prevalence of
which has increased in recent years because of the emergence of triclabendazole-resistant
strains as well as changing climatic conditions. A number of F. hepatica protein antigens
are used for assessing the immune response of the definitive host for the development of
recombinant vaccines but no such vaccine has been commercialised yet. Glycans that may
contribute to the antigenic, immunological and protective properties in F. hepatica have
not been characterised. Using a panel of plant lectins with defined sugar binding specifici-
ties alongside mass spectrometric analysis, we found that high mannose and oligomannose
N-glycans are the most abundant in the surface of the juvenile fluke and identified eigh-
teen proteins likely to be glycosylated. Additionally, we found that the proteases cathepsin
B1 and L3 contain a glycosylation site occupied by an unusually short Man2GlcNAc2 N-
glycan. This work is the starting point for understanding how F. hepatica glycans interact
with the definitive host at the initiation of infection. Additionally, it provides useful infor-
mation for including glycans in the design of new vaccine candidates.
Introduction
The trematode Fasciola hepatica, commonly known as the liver fluke, is widely distributed
across five continents and is responsible for fasciolosis in livestock and humans. It has a large
economic impact on the livestock industry, causing production losses in terms of reduced milk
yield, liver condemnation and problems with animal fertility among others [1–3]. The World
Health Organisation (WHO) has estimated an increase of 11% in the prevalence of human fas-
ciolosis over the last decade, with more than 2.6 million people infected globally [4]. To date,
the chief method of control has been administration of flukicidal drugs, with triclabendazole
the most frequently used. However, in recent decades, triclabendazole resistance in fluke popu-
lations has been reported globally [5]. This, together with the goal of reducing drug use in
food-producing animals [6] has encouraged the scientific community to investigate new meth-
ods of control. The development and use of vaccines against F. hepatica would be a more sus-
tainable and environmentally friendly future alternative to anthelmintic drugs.
The tegument (Teg) and the excretory/secretory (ES) components are important sources of
F. hepatica antigens with the highest potential as vaccine targets. Native F. hepaticamolecules
identified and isolated using proteomic approaches have in some cases been able to produce
significant reductions in liver fluke burden and reduced pathology not only in small animal
models but also in cattle and sheep. For example, the native members of the Cathepsin clade
FhCL1, FhCL2 and FhCL3—some of the most intensively studied vaccine candidates—were
able to induce protection in experimental models including rats [7], and in cattle [8] and sheep
[9]. In addition, they were able to decrease liver fluke egg viability by as much as 98% in vacci-
nated animals [8,10]. Other important vaccine candidates investigated included peroxiredoxin
(PRX), paramyosin, glutathione S-transferase (GST), fatty acid-binding protein [11] and
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leucine-aminopeptidase [9]. In many cases, the protective capacity of recombinant versions
was lower than that of the native proteins, or more variable between one study and another.
For example, the recombinant version of FhCL1 induced 48% protection in cattle [12] in a
small-scale field trial but did not provide protection in small ruminants [13,14]. Although ani-
mal variability and differences in vaccine formulation are key factors that could explain these
discrepancies [15], it is also likely that there are differences in terms of protein folding or post-
translational modifications between native and recombinant proteins which influence protec-
tive capacity. Glycosylation is one of the main post-translational modifications that occurs fol-
lowing protein synthesis, and glycosylation pathways of prokaryotic and simple eukaryotic
vectors used to produce recombinant vaccine candidates are substantially different from those
of the parasite itself [16].
Glycomic studies of other trematodes, such as Schistosoma mansoni [17] and Opisthorchis
viverrini [18] and most recently Echinostoma caproni [19,20] have led to a deeper understand-
ing of the structural and functional aspects of glycans in this class of helminths. The immuno-
modulatory properties of F. hepatica glycans and glycoconjugates are now also being studied;
for example, their apoptotic effect in peritoneal eosinophils and macrophages in vitro has been
demonstrated [21,22] along with their induction of arginase 1, IL-10 and TGF-β transcription
in peritoneal macrophages, indicators of M2a macrophages [23]. Recently, the requirement of
F. hepatica glycans to influence dendritic cell (DC) maturation and to inhibit IFN-γ production
by splenocytes from infected animals has been reported [24,25].
It has been shown that the adult stage of F. hepatica contains at least several types of glycans
and glycan motifs such as fucosylated LacdiNAc (LDN-F) motifs [26], mucin-type O-glycosy-
lated proteins [27], the glycolipid CD77 [28] and other glycoceramides [29,30]. Even though
the full range of F. hepatica glycoconjugates has not been characterised, the presence of various
glycans has been confirmed by lectin binding studies not only in adult stages [25,29,31] but
also in the other lifecycle stages (miracidia, rediae, sporocysts) [32–34]. However, systematic
studies of glycosylation in the NEJ have not yet been carried out. It is also important to charac-
terise the protein backbones containing these glycans and to verify whether proteins used pre-
viously as vaccine candidates are glycosylated. Finally, the potential immunomodulatory
properties of these glycans are important both for our understanding of the immunology of fas-
ciolosis and for vaccine development.
The goals of this work were to describe the glycosylation patterns of NEJ tegumental (NEJ-
Teg) and somatic (NEJSom) fractions using lectin-affinity techniques and perform a deeper
glycan characterisation of NEJTeg using mass spectrometry (MS). We also identified NEJ pro-
teins that are glycosylated and assessed whether they have been previously described as anti-
genic/vaccine candidates.
Materials and Methods
In vitro excystation of metacercariae and isolation of NEJTeg and
NEJSom
F. hepaticametacercariae with their outer cyst wall removed were obtained from Baldwin Aqua-
tics, Inc. (Monmouth, Oregon) and stored at 4°C until use. Excystation of metacercariae was per-
formed as described previously with minor modifications [35]. Approximately 15,000 excysted
NEJ were used for Teg isolation as previously described [36]. Briefly, NEJ were washed three
times in PBS followed by incubation for 30 min at room temperature with 1ml of 1% Nonidet
P40 (NP40) in PBS. They were then centrifuged at 300 x g for 5 min and the supernatant col-
lected. NP40 was removed from the supernatant with 0.3 g of Bio beads (Bio-Rad) according to
the manufacturer’s recommendations. The pellet obtained after Teg removal, containing
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denuded NEJ, was suspended in 1 ml of RIPA buffer (Sigma-Aldrich) and used for somatic frac-
tion isolation as previously described [37]. After incubation, both samples were centrifuged at
1000 x g for 5 min and supernatants, which correspond to the NEJTeg and NEJSom, respectively,
were aliquoted and stored at -80°C. The protein content was determined by the bicinchoninic
acid assay (Thermo Fisher Scientific) according to the manufacturer’s recommendations.
Lectin fluorescence staining
The protocol for lectin fluorescence staining was adapted from that described [38]. After fixa-
tion in 10% buffered paraformaldehyde solution, NEJ were incubated overnight with 10 ml of
1% BSA, 0.1% sodium azide in PBS (blocking solution) at 4°C. Following extensive washing in
PBS, they were suspended in 500 μl of 0.1% BSA, 0.1% sodium azide in PBS (ABD buffer) and
aliquoted in batches (40 per batch). NEJ were then incubated overnight in the dark at RT with
a panel of FITC conjugated-lectins (Vector Labs) diluted in ABD buffer in a ratio at 1:200. The
lectins used and their nominal binding specificity are listed in Table 1. Specific lectin binding
Table 1. Origin and nominal specificity of the lectins used for F. hepaticaNEJTeg and NEJSom lectin blot and lectin fluorescence staining.
Lectin Origin Nominal speciﬁcity Speciﬁc inhibitors
AALa Aleuria aurantia Fuc (α1–6)GlcNAc and Fuc (α1–3) LacNAc Fuc 0.2 M
ConAa Canavalia ensiformis α-Man; α-Glc Man 0.5 M + Glc 0.5 M
LCAa Lens culinaris α-Man; α-Fuc Man 0.5 M + Glc 0.5 M
PSAa Pisum sativum α-Man; α-Fuc Man 0.5 M + Glc 0.5 M
GNLa Galanthus nivalis (α1–3)Man Man 0.5 M + Glc 0.5 M
WGAa Triticum vulgaris GlcNAc oligomers; NeuAc GlcNAc 0.5 M
S-WGAa Triticum vulgaris GlcNAc GlcNAc 0.5 M
GSL IIa Griffonia simplicifolia α- or β-GlcNAc GlcNAc 0.5 M
RCA-
120a
Ricinus communis Gal (pref β); GalNAc Gal 0.5 M
GSL Ia Griffonia simplicifolia α-GalNAc; α-Gal Gal 0.5 M+ GalNAc 0.5 M
SBAa Glycine max α- or β-GalNAc; Gal GalNAc 0.5 M
DBAa Dolichos biﬂorus α-GalNAc GalNAc 0.5 M
PNAa Arachis hypogaea Gal (β1–3)GalNAc (= T-antigen”) on/or O-Glycans Gal 0.5 M
PHA-La Phaseolus vulgaris Oligosaccharide Acetic acid 0.1 M
PHA-Ea Phaseolus vulgaris Oligosaccharide Acetic acid 0.1 M
Jacalina Artocarpus integrifolia Gal (β1–3)GalNAc (= T-antigen”) on/or O-Glycans Gal 0.5 M
ECLa Erythrina cristagalli LacNAc; Gal Lac 0.5 M
SJA Sophora japonica (pref. β-) GalNAc and Gal GalNAc 0.2 M
UEA I Ulex europaeus α-Fuc Fuc 0.1 M
VVL Vicia villosa α- or β-GalNAc (terminal) and α- GalNAc-Ser/Thr (= Tn-antigen)
and Gal(α1–3)GalNAc
GalNAc 0.2 M
DSL Datura stramonium (β1–4) GlcNAc oligomers (chitobiose etc); LacNAc Chitin Hydrolase
LEL Lycopersicon
esculentum
GlcNAc oligomers Chitin Hydrolase
MAL II Maackia amurensis (α2–3)NeuAc Human glycophorin
SNA Sambucus nigra NeuAc(α2–6)Gal > (α2–3); Lac/Gal Lac 0.5M in buffered saline followed by Lac
0.5M in acetic acid
STL Solanum tuberosum GlcNAc oligomers; bacterial cell walls Chitin Hydrolase
aLectins with their speciﬁc inhibitors for each lectin employed in ﬂuorescence staining: Fuc (Fucose), Man (Mannose), Glc (Glucose), Gal (Galactose), Lac
(Lactose), GlcNAc (N-Acetyl-Glucosamine), GalNAc (N-Acetyl-Galactosamine), LacNAc (N-Acetyl-Lactosamine), NeuAc (Neuraminic acid = sialic acid),
Ser (serine), Thr (threonine).
doi:10.1371/journal.pntd.0004688.t001
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was confirmed by pre-incubation of each lectin with the appropriate sugar inhibitor for 2 h at
the concentration provided in Table 1. After incubation and extensive washes with ABD solu-
tion, NEJ were placed in Vectashield mounting medium with DAPI (Vector Labs). Slides were
viewed with a LEICA DM IL LED using 10x and 40x HI PLAN I objectives (Leica Microsys-
tems) equipped with an epifluorescence source and filter system for FITC and DAPI fluores-
cence. Images were merged using Adobe Photoshop CC software version 14.0 x 64.
Lectin blot analysis
NEJTeg and NEJSom (10 μg) were analysed by SDS–PAGE using 4–20% gradient Tris-glycine
precast gels (Thermo Fisher Scientific) in a vertical electrophoresis system (ATTO) for 90 min
at 40 mA. Gels were either subjected to silver staining or transferred to nitrocellulose mem-
brane using the iBlot system (Thermo Fisher Scientific). After blocking with 5% BSA in PBS
for 1 h, membranes were incubated with biotin-conjugated lectins (Vector Labs) for 1 h. For
secondary detection, membranes were washed and incubated with IRDye-labelled streptavidin
(LI-COR Biosciences) for 1 h. Specific lectin binding was confirmed as described previously. A
membrane incubated with IRDye-labelled streptavidin only was performed as an additional
negative control in order to confirm lack of reactivity between NEJ extracts and streptavidin.
Images were acquired using an Odyssey infrared scanning imaging system (LI-COR
Biosciences).
N-glycan release, purification, labelling and exoglycosidase treatment
NEJTeg (glyco)proteins (500 μg) were enzymatically fragmented by using trypsin-coupled
beads (GE Healthcare Life Sciences) following the manufacturer’s instructions. Four μl of 1 U/
μl N-glycosidase-F (PNG-F) (Roche) were added to the sample and incubated for 24 h at 37°C
while shaking. The N-glycan mixture released by the PNG-F was purified with a C18 Reverse
phase (RP) cartridge (500 mg; JT Baker) and a carbon cartridges (150 mg Carbograph; Grace)
as previously described [39].
The (glyco)peptides remaining in the C18 RP cartridge were eluted, dried in a Speed-Vac
(Thermo Fisher Scientific) and dissolved in 50 μl of 1 M sodium acetate solution (pH 4.5). Fol-
lowing pH adjustment to 4.5, 2 μl of N-glycosidase-A (PNG-A, 1 U/μl; Roche) were added to
the sample and incubated for 48 h at 37°C while shaking. The N-glycan mixture released by the
PNG-A treatment was purified and incubated overnight as described previously [39]. The puri-
fied N-glycans were subsequently labelled with the fluorophore 2-aminobenzoic acid (2-AA)
(Sigma-Aldrich), as described elsewhere [40]. The labelled N-glycans were brought to 75%
AcN and loaded on Biogel P10 (Bio-Rad) columns conditioned with 80% AcN. N-glycans were
eluted with 400 μl of dH2O and dried down in a Speed-Vac. AA-labelled PNG-F released gly-
cans (1 μl/treatment) were incubated in a volume of 10 μl for 24 h at 37°C in 250 mM sodium
citrate buffer with one of the following exoglycosidases: α-mannosidase from jack bean
(15 μU/μl; Sigma Aldrich), β-galactosidase from jack bean (5 μU/μl; Prozyme) or recombinant
β-N-acetylglucosaminidase (4 μU/μl; New England Biolabs).
MS and glycan composition determination
PNG-F and PNG-A released N-glycans were dissolved in 50 and 25 μl of dH2O respectively.
One μl of each sample was spotted on a matrix-assisted laser desorption ionisation (MALDI)
polished steel targeted plate (Bruker Daltonics) using 2,5-dihydroxybenzoic acid (DHB; 20 mg/
ml in 30% AcN) as matrix. Samples were analysed with an Ultraflex II MALDI–time-of-flight
(MALDI-TOF) mass spectrometer (Bruker Daltonics, Bremen, Germany) operating in the neg-
ative-ion reflectron mode. For assessing the results of exoglycosidase treatments, digestion
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products were purified using a HILIC Ziptip column (Millipore) following the manufacturer’s
instructions. Glycans were eluted directly to a MALDI target plate with 10 mg/ml DHB in 50%
AcN containing 0.1% TFA and analysed in the negative-ion reflectron mode. Glycopeakfinder
(http://www.glyco-peakfinder.org) was used to define glycan composition.
NEJTeg glycoprotein biotinylation and isolation
The glycan components of NEJTeg-derived glycoproteins were biotinylated with EZ-link
Hydrazide-Biotin (Thermo Fisher Scientific) according to the manufacturer’s instructions. The
biotinylated glycoproteins (B-NEJTeg) were purified from the rest of the NEJTeg components
by affinity chromatography using monomeric avidin agarose (Thermo Fisher Scientific). The
flow through was collected as avidin-unbound fraction (A-UB-NEJTeg) and the avidin-bound
fraction (A-BB-NEJTeg) separated from the resin following a previously reported protocol
[41]. All fractions were concentrated and buffer exchanged in PBS using Pierce Concentrator
3K MWCO (Thermo Fisher Scientific). BCA assays were performed in order to quantify the
protein content. SDS–PAGE, silver staining and streptavidin blots were used in order to assess
the quality of the biotinylation reaction.
Glycoprotein identification
Total NEJTeg (50 μg), B-NEJTeg and A-BB-NEJTeg, samples (10 μg each) were fractionated
by 12% SDS-PAGE. The bands contained in B-NEJTeg and A-BB-NEJTeg fractions were
stained with SYPRO Ruby gel stain (Bio-Rad) according to the manufacturer’s instructions.
Bands were excised and a liquid handling station (MassPrep; Waters) was used with sequenc-
ing-grade modified trypsin (Promega) according to the manufacturer’s instructions, for in-gel
protein digestion. Peptide extracts were then dried by evaporation in a Speed-Vac. Liquid
Chromatography and tandem mass spectrometry (LC-MS/MS) was carried out with a linear
trap quadrupole (LTQ) mass spectrometer connected to a Thermo Surveyor MS pump and
equipped with a nano electrospray ionisation (ESI) source (Thermo Fisher Scientific) [42].
For total NEJTeg, bands were stained with a Coomassie blue kit (Thermo Fisher Scientific),
excised and digested as described [43]. The proteomics analysis of the NEJTeg extract was per-
formed by nano reverse-phase (RP) LC-ESI-ion trap MS/MS, consisting of an Ultimate 3000
RSLC nano LC system (Thermo Fisher Scientific) coupled to a Captive Spray nano Booster
(Bruker Daltonics) according to previous protocol [43].
All MS/MS spectra were analysed with Mascot (version 2.4.0; Matrix Science), set up to
search against two proprietary Fasciola hepatica databases, assuming digestion with trypsin
with 1 miss cleavage allowed: (1) a database comprising the gene models identified from the F.
hepatica genome (101,780; [44]) (2) a database comprising all available EST sequences
(633,678 entries). Fragment and parent ion mass tolerance were set at 0.100 Da. Carbamido-
methylation of cysteine was specified as a fixed modification. Dehydration of the N-terminus,
Glu->pyro-Glu of the N-terminus, ammonia-loss of the N-terminus, Gln->pyro-Glu of the
N-terminus, deamidation of Asn and Glu, oxidation of Met, Arg and Thr and biotinylation of
Lys were specified as variable modifications. Scaffold v4.34 (Proteome Software Inc.) was used
to validate MS/MS based peptide and protein identifications. Peptide identifications were
accepted if they could be established at greater than 95% probability to achieve a 0% false dis-
covery rate (FDR) by the Peptide Prophet algorithm [45] with Scaffold delta-mass correction.
Protein identifications were accepted if they could be established at greater than 95% probabil-
ity to achieve a 0% FDR and contained at least 2 identified peptides. Protein probabilities were
assigned by the Protein Prophet algorithm [46]. Proteins that contained similar peptides and
could not be differentiated based on MS/MS analysis alone were grouped to satisfy the
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principles of parsimony. Putative N-glycosylation sites of the glycoproteins detected in the
A-BB-NEJTeg and from the cathepsins identified in total NEJTeg were searched using the
NetNGlyc 1.0 Server (www.cbs.dtu.dk) [47].
Prediction of tryptic peptide of cathepsins with putative N-glycosylation
and in-depth glycopeptide MS analysis
Bands from the NEJTeg sample in which the presence of cathepsins were confirmed by MS/MS
were selected for in-depth glycopeptide analysis. The amino acid sequence and the molecular
weight of the N-glycosylated tryptic peptides of the cathepsins were predicted using the online
tool http://web.expasy.org/peptide_mass [48] taking into account carbamidomethylation of
cysteine, and methionine oxidation as a variable modification.
For nano-RP-LC-ESI-ion trap-MS/MS the peptides and glycopeptides extracted from the
cathepsin bands were loaded on a trap column (Acclaim PepMap100 C18 column, 100 μm × 2
cm, C18 particle size 5 μm, pore size 100 Å, Thermo Fisher Scientific) for concentration prior
to separation on an Acclaim PepMap RSLCnano-column (75 μm × 15 cm, C18 particle size
2 μm, pore size 100 Å, Thermo Fisher Scientific). The column was equilibrated at RT with elu-
ent A (0.1% formic acid in dH2O) at a flow rate of 700 nL/min. After injection of the sample,
elution conditions were switched to 10% solvent B (95% AcN, 5% dH2O), followed by a gradi-
ent to 60% B in 45 min and a subsequent isocratic elution of 10 min. The eluate was monitored
by absorption at 215 nm. MS was performed on an AmazonSpeed ion trap (Bruker Daltonics)
containing an electron-transfer dissociation (ETD) module (PTM Discovery System). The MS
instrument was operated in positive ion mode with a mass window ofm/z 400–2000. The five
most abundant ions in an MS spectrum were selected for MS/MS analysis by collision-induced
dissociation (CID) using helium as the collision gas, with ion detection overm/z 300–1300. For
the electrospray (1300 V), solvent evaporation was achieved at 180°C with N2 stream at a flow
rate of 3 L/min.
In manually selected cases glycopeptide sequence analysis was performed using ETD as
described [49]. The selected glycopeptide ions were isolated in the ion trap and fluoranthene
radical anions were formed by negative chemical ionisation (nCI) with methane as mediator.
For the accumulation (typical accumulation time 5 ms) of fluoranthene reactant anions in the
ion trap, the polarity was switched to negative mode. Glycopeptide cations and fluoranthene
anions were incubated in the ion trap for 70 ms, allowing electron transfer, followed by the reg-
istration of the ETD fragment ion spectrum form/z 150 to 3000. Selected MS/MS spectra of
CID and ETD were interpreted manually using Bruker Daltonics Data Analysis software (Bru-
ker Daltonics).
Protein sequence alignment
Multiple sequence alignment of selected proteins was performed using Clustal Omega [50]
using default parameters. Pairwise sequence alignment was carried out using EMBOSS
matcher, based on the Bill Pearson's align application, version 2.0u4 [51].
Accession numbers
BN1106_s6570B000051
BN1106_s4187B000061
Fh_Contig2249
BN1106_s1922B000122
BN1106_s7612B000030
BN1106_s1518B000071
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BN1106_s7307B000022
BN1106_s25B000189
BN1106_s1612B000138
BN1106_s462B000766
BN1106_s2763B000063
BN1106_s3008B000074
BN1106_s1081B000242
BN1106_s5172B000090
BN1106_s666B000200
BN1106_s9461B000006
BN1106_s4565B000032
BN1106_s10139B000014
BN1106_s3227B000227
BN1106_s10667B000018
BN1106_s5100B000033
BN1106_s8462B000006
BN1106_s6570B000050
BN1106_s4482B000044
gi|27526823
Results
Mannose, fucose and the mucin-type core-1 (also known as T-antigen)
were the main terminal carbohydrate motifs detected and localised by
lectin fluorescence and lectin blot techniques
The main components of the F. hepatica Teg are glycoproteins [52]. However, the nature of the
different glycans and the identity of individual glycoproteins are still unknown. For that reason,
a panel of 17 fluorescein-labelled plant lectins were employed in fluorescence microscopy
experiments for glycan localisation (Fig 1). In parallel, lectin blots were used to identify and
compare protein bands carrying glycans.
The most dominant protein bands detected in NEJTeg by silver staining had an apparent
molecular weight between 25–37, 50–75 and 100 kDa (Fig 1A). This was consistent with the
broad range of bands detected in the blots (Fig 1B), indicating that the majority of the NEJTeg
components were glycoproteins. Indeed, this recognition was probed with the mannose
(Man)-binding lectins ConA and GNL, all Man and fucose (Fuc)-binding lectins (AAL, LCA
and PSA), the Gal- binding lectins GSL-I and all the T-antigen-binding lectins (PNA and Jaca-
lin) suggesting the abundance of these terminal carbohydrate motifs on these NEJTeg-derived
glycoproteins. The exclusive 25 and 37 kDa pattern detected by the lectins PHA-L, PHA-E,
GSL-II, SJA, DBA, ECL (Fig 1B), UEA and SJA incubated membranes (S1 Fig), suggested the
presence of complex glycan mixture and complex glycosylation patterns in these protein
bands.
Lectin binding revealed that glycans were distributed uniformly on the parasite surface,
but most intensely on the tegumental spines. Strong carbohydrate recognition at the oral
and ventral suckers was detected by PNA, Jacalin, ConA, PSA and GSL-I (Fig 1B), suggesting
the possible role of Man, Fuc and Gal/GalNAc decorated glycoproteins in adhesion and
nutrient intake from the host. Another lectin (SBA) bound to a variety of high molecular
sized glycoproteins (Fig 1B) with terminal Gal or GalNAc located at the ventral sucker and
its periphery.
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GSL-I, SBA, PNA and Jacalin lectins exhibited differences in
glycosylation between NEJTeg and NEJSom
To provide additional information regarding the distribution of F. hepatica glycoproteins, NEJ-
Teg and NEJSom fractions were compared by silver staining and lectin blots. Similarities
observed by silver staining in the migratory components between the NEJTeg (Fig 1A) and
NEJSom (Fig 2A) and by eleven lectin blots indicated that there were some (glyco)proteins
shared in both extracts. In addition, a small group of lectins did not recognise glycoproteins in
any of the NEJ extracts, i.e. the Gal-binding lectin RCA-120, all NeuAc-binding lectins (SNA
and MAL-II) and the majority of the GlcNAc-binding lectins (DSL, LEL and STL) (S1 Fig),
Nevertheless, the lectins GSL-I, SBA, PNA and Jacalin revealed significant differences in glyco-
sylation of NEJSom (Fig 2B). For example, in the NEJSom, PNA, which shows a similar pattern
Fig 1. Glycoprotein detection and localisation on F. hepaticaNEJTeg by lectin blot and lectin fluorescence staining. The total protein profile of F.
hepaticaNEJTeg (Teg) was revealed after SDS-PAGE fractionation and visualised in-gel by silver staining (A). Fixed NEJ and nitrocellulose membranes
were incubated with FITC-labelled or biotinylated-conjugate lectins respectively. Specific lectin binding to glycans with terminal Fuc- (AAL, LCA, PSA), Man-
(ConA, GNL), Galβ1-3GalNAc- (Jacalin, PNA), Gal/GalNAc- (RCA-120, GSL-I, SBA, DBA), Lac- (ECL), oligosaccharides- (PHA-E, PHA-L) or GlcNAc-
(WGA, sWGA, GSL-II) motifs is shown. Oral sucker (or) and ventral sucker (vs) are identified with arrows (B). Negative controls consisted of nitrocellulose
membranes without lectin incubation (1), nitrocellulose membranes incubated with biotinylated-conjugate lectins that were previously incubated with their
specific inhibitors (2) and fixed NEJ incubated with FITC-labelled lectins that were previously incubated with their specific inhibitors (3). The list of lectins used
and their corresponding inhibitors are detailed in Table 1 (C). Nitrocellulose membranes were exposed to IRDye-labelled streptavidin to reveal positive lectin
binding (green) at various molecular weights (markers in red). Glycoprotein profiles were visualised by IR system. Epifluorescence microscope was
employed to detect glycan localisation (green) and DNA was counterstained with DAPI (blue). Merged image of both micrographs is included for each lectin.
Scale bar = 100 μm
doi:10.1371/journal.pntd.0004688.g001
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of recognition as Jacalin, bound the 37 kDa band as observed in the NEJTeg, but also two addi-
tional prominent (glyco)protein bands at 25 and 75 kDa. These results suggest the presence of
T-antigen in the internal organs of the NEJ.
High mannose and oligomannose are the most dominant N-glycans in
NEJTeg
As the NEJTeg showed high (glyco)protein abundance and complexity, we decided to perform
an in-depth characterisation of the protein-derived glycans of this preparation by MALDI--
TOF-MS. In order to characterise the tegumental N-glycans, these were enzymatically released
and MALDI-TOF-MS spectra were recorded before and after specific exoglycosidase treat-
ments (Fig 3).
The spectrum obtained from PNG-F released N-glycans showed 5 dominant peaks withm/z
values 1354.63, 1516.69, 1678.49, 1840.81 and 2002.87 [M−H]− (Fig 3A). These peaks corre-
sponded to glycans with composition H5N2, H6N2, H7N2, H8N2 and H9N2 (hexose (H), N-
acetylhexosamine (N)) respectively, suggesting, in line with the previous lectin binding affinity
results, a clear dominance of high mannose N-glycans in NEJTeg. This composition was con-
firmed after exoglycosidase treatment as all these dominant peaks completely disappeared or
drastically decreased after α-mannosidase treatment while peakm/z 1030.32 [M−H]−, which
corresponded to the N-glycan with composition H3N2, became the most dominant ones in the
spectrum (Fig 3B).
Some compositions suggestive of complex type N-glycans were detected in the MALDI-TOF
MS of the NEJTeg preparation, with lower relative abundance. The comparison of the PNG-F
spectra before and after β-N-acetylglucosaminidase treatment confirmed the presence of termi-
nal, unsubstituted GlcNAc on the antennae of glycans withm/z 1379.66 [M−H]− (H3N3F1)
(deoxyhexose (F)) andm/z 1582.75 [M−H]− (H3N4F1) seen in Fig 3A but undetectable in Fig
3C. This observation also confirms that the Fuc residue found in these glycans is attached to
the chitobiose core. We assume that the Fuc is α1-6-linked to GlcNAc-1 since α1-3-linkage
would have rendered the glycans resistant to PNG-F. Both PNG-F glycan spectra before and
after β-galactosidase treatment were very similar suggesting that no terminal β-Gal was present
which was in line with the negative binding detection of RCA-120 lectin. The spectrum
obtained from PNG-A released N-glycans (S2 Fig) showed a similar glycan pattern as the
Fig 2. Glycosylation of F. hepaticaNEJSom. The total protein profile of F. hepaticaNEJSom (Som) was revealed after SDS-PAGE fractionation and
visualised in-gel by silver staining (A). NEJSom preparations were SDS-PAGE fractioned, transferred to nitrocellulose membranes and incubated with the
biotinylated-labelled lectins GSL-I, SBA, PNA and Jacalin (B). Negative controls consisted of nitrocellulose membranes without lectin incubation (1) and
nitrocellulose membranes incubated with biotinylated-conjugate lectins that were previously incubated with their specific inhibitors (2). The list of lectins used
and their corresponding inhibitors are detailed in Table 1 (C). An additional incubation with IRDye-labelled streptavidin was used to detect positive lectin
binding at different molecular weights (red markers). Glycoproteins were revealed by infrared imaging.
doi:10.1371/journal.pntd.0004688.g002
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PNG-F release indicating that no specific PNG-F resistant core α1–3 fucosylated glycans are
present in NEJTeg. All peaks identified and their corresponding glycan structures are described
in Fig 4.
The NEJ FhCL3 and FhCB3 were detected in the glycosylated NEJTeg
fraction alongside other important immunomodulatory molecules
To specifically identify which NEJTeg proteins are glycosylated, we biotinylated the glycan
structures contained in NEJTeg glycoproteins and then selectively isolated the glycoprotein
components by affinity monomeric avidin chromatography from the total NEJTeg protein
pool. The efficiency of the glycoprotein biotin-labelling (B-NEJTeg) and isolation of the pro-
teins (A-UB-NEJTeg) and glycoproteins (A-BB-NEJTeg) was confirmed by comparing the
protein profile between fractions using silver staining and the streptavidin blot (S3 Fig).
Proteomic MS analysis identified a total of 20 proteins in B-NEJTeg and A-BB-NEJTeg
preparations whose molecular weights correlated with protein bands found by silver staining.
A total of eighteen proteins were identified in the A-BB-NEJTeg (glycosylated) fraction
(Table 2). There were potentially important F. hepaticamolecules identified in this fraction
including the asparaginyl endopeptidase legumain-1, the antioxidants GST and PRX and heat
shock protein 70 (HSP70). It is noteworthy also to highlight the identification of the proteases
FhCB3 and FhCL3 in the glycosylated fraction. Two isoforms of FhCL3 were identified in this
extract. All the glycoproteins except GST and Histone H4 were predicted to contain potential
N- glycosylation sites. GST and Histone H4 were predicted not to contain N-glycosylated sites,
suggesting that they are O-glycosylated.
Most of the NEJ specific cathepsins have been shown to contain
potential N-glycosylation
Cathepsins were the most abundant proteins found in the glycosylated fraction; due to their
pivotal role in parasite survival and since cathepsins from the same family have been employed
as vaccine candidates, we investigated the total NEJTeg material focusing on evaluating cathep-
sin-specific glycosylation at the glycopeptide level.
After selecting and excising bands found at the predicted molecular weight of the cathepsins
(Fig 5A), tryptic in-gel digestion and protein identification was performed in order to select
cathepsins to be examined in detail. We were able to identify several cathepsins, including
FhCL3, FhCB1, FhCB2, FhCB3 and partial novel FhCB protein (Fig 5B). The NetNGlyc 1.0
server suggested the presence of one potential N-glycosylation site in the amino acid sequence
of two of the FhCL3 members (BN1106_s3008B000074 and BN1106_s10139B000014), at the
positions N151 and N255, respectively. FhCB1, FhCB2 and the partial novel FhCB were pre-
dicted to contain two N-glycosylation sites at positions N145 and N156 for partial novel FhCB,
N80 and N315 for FhCB1 and N345 and N356 for FhCB2. FhCB3 was predicted to have four
N-glycosylation sites at positions N180, N223, N336 and N453. However, one of the FhCL3
(BN1106_s4187B000061) and the partial FhCB (BN1106_s8462B000006) were predicted not
to be N-glycosylated. When 0 missed cleavages were allowed, tryptic peptide masses containing
potential N-glycosylation vary from 617.337 to 2658.15 kDa.
Fig 3. MALDI-TOF-MS spectra of AA-labelledN-linked glycans of F. hepaticaNEJTeg before and after exoglycosidase treatments.N-glycans
released from NEJTeg using PNG-F were labelled with fluorophore 2-aminobenzoic acid (2-AA). MS spectra of AA-labelledN-glycans were acquired by
MALDI-TOF-MS without exoglycosidase treatment (A) and after α-mannosidase (B), β-N-acetylglucosaminidase (C) and β-galactosidase (D) treatments.
Unidentified peaks are represented with an asterisk (*). Green circle, Man; blue square, GlcNAc; red triangle, Fuc.
doi:10.1371/journal.pntd.0004688.g003
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Once the cathepsin members and the relevant tryptic peptides with potential N-glycosyla-
tion sites were identified, we wanted to determine whether these glycosylation sites were occu-
pied by glycans and also the composition of the glycans involved.
One of the glycosylation sites of the FhCB1 and one of the FhCL3
proteins is occupied by a Manα1-3/6Manα1-4GlcNAcβ1-4GlcNAcβ1- N-
glycan
All tryptic glycopeptides from the four bands were applied to a RP-nano-LC column coupled
to an ion-trap MS/MS system and fragmented in the auto-MS/MS mode. A parent-ion ofm/z
829.50 [M+3H]3+ in the 20.1 min elution was detected in band 2, giving rise to oxonium glycan
fragment ions atm/z 366.09 [M+H]+ (H1N1) andm/z 528.21 [M+H]+ (H2N1), which indi-
cated the presence of the terminal di-mannosylated HexNAc element. Further inspection of
the CID-MS/MS spectrum of the parent ionm/z 829.50 [M+3H]3+ indicated the presence of a
glycan with the composition H2N2 linked to a peptide of 1755 Da (Fig 6A). [M+3H]3+ frag-
ment ions were observed for this peptide carrying N2 (m/z 721.28) or a H1N2 trisaccharide
Fig 4. List of the characterised F. hepaticaNEJTegN-glycans identified by MALDI-TOF-MS.
Composition of glycan subsets expressed in terms of hexose (H), N-acetylhexosamine (N) and deoxyhexose
(F). The five most prominent peaks shown in Fig 3A are indicated (#). Red triangle, Fuc; green circle, Man;
yellow circle, Gal; blue square, GlcNAc; yellow square, GalNAc.
doi:10.1371/journal.pntd.0004688.g004
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(m/z 775.31) structure of an Asn-linked glycan. Furthermore, a [M+2H]2+ fragment ion atm/z
980.40 (N1-peptide) was fully in line with the presence of an N-glycan.
The CID-MS/MS spectrum of another parent ionm/z 878.70 [M+3H]3+ in the 19.9 min elu-
tion indicated the presence of another sort of glycan with the composition F1H2N2 linked to a
peptide with the same mass as the previous peptide described (Fig 6B). [M+3H]3+ fragment
ions were observed for this peptide carrying a Fuc attached to the N2 (m/z 770.75) or a
F1H1N2 tetrasaccharide (m/z 824.64) structure of an Asn-linked glycan. In addition, a series of
[M+2H]2+ fragment ions atm/z 1243.62 (H2N2-peptide), 1235.44 (F1H1N2-peptide), 1162.51
(H1N2-peptide), 1154.60 (F1N2-peptide), 1081.49 (N2-peptide), 1052.96 (F1N1-peptide) and
979.94 (N1-peptide) were fully in line with the presence of the fucosylated version of the
dimannosyl core N-glycan.
The mass of the peptide containing the N2H2 and F1N2H2 N-glycans matched the mass of
one of the tryptic peptides of FhCB1 (BN1106_s6570B000050). To obtain information on the
glycopeptide sequence and identify the cathepsin that contained the N-glycan, the ETD-MS/
MS spectra of the same parent ionsm/z 829.83 [M+3H]3+ and 878.7 [M+3H]3+ were recorded
in which peptide cleavages were predominantly observed while leaving the glycosidic linkages
intact [53]. For the parent ionm/z 829.83 [M+3H]3+ (Fig 6C), the c’-type as well as z’-type ions
arising from peptide bond cleavages provide partial sequences of the peptide backbone from
the N- and C-terminal side, respectively. As annotated in Fig 6C, the VSENDLPESFDAR
Table 2. Characterisation of F. hepaticaA-BB-NEJTeg glycoprotein composition detected following glycoprotein biotinylation, affinity chromatog-
raphy isolation and LC-MS/MS analysis.
Protein Identiﬁer ID prob
(%)
UP
B-NEJTEG
UP
A-BB-NEJTEG
Pot. N-
Glyc
FhCB3 BN1106_s6570B000051 100 5 8 4
FhCL3 BN1106_s4187B000061 100 4 0
PRX Fh_Contig2249 100 2 3 4
Paramyosin BN1106_s1922B000122 100 2 3
Legumain-1 BN1106_s7612B000030 100 9 1
Fructose-bisphosphate aldolase BN1106_s1518B000071 100 5 1
Uncharacterised protein BN1106_s7307B000022 100 5 14
Basement membrane-speciﬁc heparan sulfate proteoglycan
core protein
BN1106_s25B000189 100 3 27
Multi-domain cystatin BN1106_s1612B000138 100 3 10
Cell polarity protein; Neurexin-1-α; Fibropellin-1 BN1106_s462B000766 100 3 2
Protein disulphide isomerase BN1106_s2763B000063 100 3 1
FhCL3 BN1106_s3008B000074 100 3 1
GST-Sigma BN1106_s1081B000242 100 3 0
Uncharacterised protein BN1106_s5172B000090 100 2 8
Lysosomal α-mannosidase BN1106_s666B000200 100 2 8
HSP70 BN1106_s9461B000006 100 2 5
Estrogen-regulated protein EP45 BN1106_s4565B000032 100 2 2
FhCL3 BN1106_s10139B000014 100 2 1
Enolase BN1106_s3227B000227 100 2 1
Histone H4 BN1106_s10667B000018 100 2 0
Potential protein N-glycosylation was determined by assessing the presence of N-glycan consensus sequons by the NetNGlyc. server
ID prob (identity probability), UP (unique peptide), B-NEJTEG (biotinylated NEJ tegument), A-BB-NEJTeg (avidin bound biotinylated NEJ tegument), Pot
N-Glyc (number of potential N-glycosylation sites)
doi:10.1371/journal.pntd.0004688.t002
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sequence can be read directly from the c2-c15 ion series, while the signals indicated with z2-z15
read the DFSEPLDNESVN(glycan)Y sequence, including the mass increment of 732 Da
accountable to the glycan H2N2. This sequence is the FhCB1 tryptic peptide (no missed cleav-
age) Y79NVSENDLPESFDAR93, containing the N-glycosylation consensus sequence NVS. On
the other hand, when the ETD-MS/MS spectrum of the parent ionm/z 878.7 [M+3H]3+ was
recorded, the VSENDLPESFDAR sequence containing the glycan F1N2H2 could not be
directly read. Taken together, the MS/MS data indicated that FhCB1 is modified at the Asn in
position N80 with a Manα1-3/6Manα1-4GlcNAcβ1-4GlcNAcβ1-Asn N-glycan. Nevertheless,
despite the strong evidence of the presence of a monofucosylated version of the same N-glycan
Fig 5. Identification of F. hepatica cathepsins in NEJTeg.NEJTeg was loaded in SDS-PAGE and stained with Coomassie Blue in order to stain protein
bands (A). Bands 1 (B1), 2 (B2), 3 (B3) and 4 (B4), were excised, tryptic digested and identified with LC-MS/MS analysis. PotentialN-glycosylation sites (Pot
N-gly) and monoisotopic mass of the tryptic peptides containing glycosylation were predicted (B). UP (unique peptide).
doi:10.1371/journal.pntd.0004688.g005
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attached to the FhCB1 in CID-MS analysis, its confirmation remained inconclusive by
ETD-MS.
For band 2, the presence of the H2N2 and F1H2N2 N-glycans attached to a peptide of
1741.2 kDa were detected in the chromatograms of the parent-ions of m/z 824.70 [M+3H]3+
in the 19.9 min elution andm/z 873.70 [M+3H]3+ in the 19.8 min elution respectively (Fig
7A and 7B). The annotation of the ETD-MS/MS spectrum of the same parent ionm/z
825.20 [M+3H]3+ showed the VSDNDLPESFDAR sequence from the c2-c15 ion series and
the DFSEPLDNDSVN(glycan)Y sequence from the z2-z15 ion series, including the mass
increment of 732 Da of the glycan H2N2 (Fig 7C). This sequence is slightly different to the
sequence of the tryptic peptide identified for FhCB1 (no missed cleavage) as there is a
replacement of the glutamic acid (E) in position 83 by an aspartic acid (D). As the new
sequence was not identified in the list of tryptic peptide containing N-glycosylation, the
sequence tag YNVSDNDLPESFDAR was analysed by BLAST (NCBI nr database). The
result showed a 100% coverage and identity hit with FhProCB2 (gi|27526823) which contains
the N-glycosylation consensus sequence NVS in position N70. Following identification of
further cathepsin B class proteins for F. hepatica and the comparative analysis of those
cathepsin sequences publically available, the FhProCB2 (gi|27526823) is consistent with the
FhCB1 sequence (S1 File, S1 Table). The slight difference (represented as at most 2 SNPs
resulting in the amino acid change from aspartic acid to glutamic acid) between the tryptic
peptide YNVSDNDLPESFDAR and the sequence corresponding to FhCB1 sequence in the
F. hepatica genome and that submitted to Genbank is most likely due to isolate differences
between the various fluke samples used for these studies.
As demonstrated for FhCB1, FhCL3 also showed firm evidence of the same glycosylation
pattern. The fragmented ions confirming the glycan structures are described in Table 3. As
with the analysis performed in tryptic peptides found in band 2, tryptic glycopeptides of the
FhCL3 (BN1106_s10139B000014, scaffold10139) were detected in bands 1 and 4. The same
glycan structures seen for FhCB1 were found to be linked to a peptide of 2113.9 kDa in the
chromatograms of the parent-ions ofm/z 949.20 and 997.80 [M+3H]3+ in the 22.2 and 22.1
min elution respectively. To investigate this further for the tryptic peptide derived from
FhCL3, ETD-MS/MS for the same parent ion in the same band was carried out. The results
showed that the ion c2-c17 and z4-z17 ion series have correspond to the sequences N(glycan)
QTLFSEQQVLDCTR and VLQQESFLTQN(glycan)QF respectively, taking into consideration
the mass increment of the H2N2 glycan. This sequence is the FhCL3 tryptic peptide (no missed
cleavage) F151QNQTLFSEQQVLDCTR167, containing the N-glycosylation consensus sequence
NQT. No definitive identification of its fucosylated version could be achieved in the ETD-MS/
MS analysis.
Sixty four additional N-glycopeptide species were found in the CID-MS/MS spectra whose
parent ions were registered in the elution times from 2.5 to 29.3 min (S2 Table). The glycans
attached to those peptides matched those observed in the NEJTeg N-glycan profile (Fig 4).
Nevertheless, the peptide mass to which the glycans were linked did not match with the masses
of the remaining tryptic peptides derived from the cathepsins.
Fig 6. Identification of shortN-glycans occupying anN-glycosylation site of FhCB1.Nano-RP-LC-ESI-ion trap-MS/MS with collision-induced
dissociation (A andB) and with electron transfer dissociation (C) of the tryptic glycopeptide Y79NVSENDLPESFDAR93 from FhCB1
(BN1106_s6570B000050). The [M+3H]3+ parent ions (blue diamonds) atm/z 829.50 (A) and 878.70 (B) of the glycopeptide carrying a glycan of composition
H2N2 and F1H2N2 respectively were selected. Fragment ions are indicated. The residual signals at them/z corresponding to [H+3H]3+ (Δ), to the doubly
charged ions that result from capture of 1 electron without dissociation [H+3H]2+ (X) and to the singly charged ions that result from capture of 2 electrons
without dissociation [H+3H]+ (*) are indicated (C). Monoisotopic masses are given. Man (green circle), GlcNAc (blue square) and Fuc (red triangle), pep
(peptide moiety).
doi:10.1371/journal.pntd.0004688.g006
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Discussion
To date, this is the first study characterising the glycans attached to the proteins in the F. hepat-
icaNEJTeg and NEJSom preparations by the systematic use of an extensive panel of lectins. In
addition, a mass spectrometric glycan characterisation of the tegumental extract was
performed.
The lack of sialic acid and the wide presence and distribution of high mannose N-glycans
and α1–6 Fuc attached to the chitobiose core of oligomannose and truncated N-glycans in the
NEJTeg was firstly detected by the binding patterns of the lectins ConA, GNL, PSA and LCA,
and confirmed later on by MALDI-TOF MS which represent an important percentage of the
total of NEJ N-glycans. The wide distribution of Man-rich N-glycans and the presence of fuco-
sylated glycans among the NEJ glycoproteins have been found in other helminths including O.
viverrini [18] Schistosoma spp. [54,55],Haemonchus contortus [56,57] and Taenia solium [58].
These glycans in S.mansoni are recognised and internalised by DC via the C-lectin type recep-
tor (CLR) DC-specific ICAM-3-grabbing non-integrin (DC-SIGN) [59], suppressing DC mat-
uration and therefore decreasing the secretion of pro-inflammatory cytokines. We propose
that glycoconjugates with terminal Man-N-glycans in the NEJTeg are likely to interact with
DCs and macrophages viaMan-specific CLRs at the early stages of infection, impairing the DC
Fig 7. Identification of shortN-glycans occupying anN-glycosylation site of on the YNVSENDLPESFDAR tryptic peptide.Nano-RP-LC-ESI-ion trap-
MS/MS with collision-induced dissociation (A andB) and with electron transfer dissociation (C) of the tryptic glycopeptide YNVSENDLPESFDAR from
FhProCB2 (gi|27526823). The [M+3H]3+ parent ions (blue diamonds) atm/z 824.70 (A) and 873.70 (B) of the glycopeptide carrying a glycan of composition
H2N2 and F1H2N2 respectively were selected. Fragment ions are indicated. The residual signals at them/z corresponding to [H+3H]3+ (Δ), to the doubly
charged ions that result from capture of 1 electron without dissociation [H+3H]2+ (X) and to the singly charged ions that result from capture of 2 electrons
without dissociation [H+3H]+ (*) are indicated (C). Monoisotopic masses are given. Man (green circle), GlcNAc (blue square) and Fuc (red triangle).pep,
peptide moiety.
doi:10.1371/journal.pntd.0004688.g007
Table 3. List of the fragment ions after CID-MS/MS of parent ions of tryptic peptide of FhCL3 (BN1106_s10139B000014).
Parent ion m/z [M+3H]3+ Fragment ions m/z Fragment charge state Ion structure Peptide Mass (Da)
949.20 H2N2-pept 2112.9
773.13 [M+3H]3+ N1-pept
840.84 [M+3H]3+ N2-pept
894.81 [M+3H]3+ H1N2-pept
1159.31 [M+2H]2+ N1-pept
1260.61 [M+2H]2+ N2-pept
997.80 F1H2N2-pept 2112.9
840.77 [M+3H]3+ N2-pept
889.11 [M+3H]3+ F1N2-pept
894.72 [M+3H]3+ H1N2-pept
943.09 [M+3H]3+ F1H1N2-pept
948.75 [M+3H]3+ H2N2-pept
1159.14 [M+2H]2+ N1-pept
1232.16 [M+2H]2+ F1N1-pept
1260.61 [M+2H]2+ N2-pept
1333.68 [M+2H]2+ F1N2-pept
1341.57 [M+2H]2+ H1N2-pept
1414.68 [M+2H]2+ F1H1N2-pept
1422.75 [M+2H]2+ H2N2-pept
1496.77 [M+2H]2+ F1H2N2-pept
doi:10.1371/journal.pntd.0004688.t003
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function and augmenting the M2a population in the peritoneal cavity, as seen with adult F.
hepatica homogenate or ES fractions [23–25], contributing to the development of the biased
Th2 that is elicited in the mammalian host [25,36].
In our study, lectin affinity techniques in some cases revealed different results than those
using other glycomics techniques with respect to identification of terminal carbohydrates. For
instance, β-N-acetylglucosaminidase and β-galactosidase treated N-glycans did not show evi-
dence of terminal β-Gal- or GalNAc- on hybrid or complex glycans in the MS spectra but did
show positive recognition of terminal Gal/GalNAc- residues on the parasite surface. This may
reflect a low abundance and potential masking by high mannose N-glycans which are very
abundant in NEJTeg. As seen in lectin blots, not many glycoproteins contain these residues.
Alternatively, lectin fluorescence staining may also indicate the presence of glycolipids as
described in adult F. hepatica [29,30], which would not have been detected in our MS spectra
results, or the O-glycosylation pattern of NEJTeg. Similar PNA recognition has been described
in adult F. hepatica [27,31] and in the nematode O. viverrini where 80% of the O-glycan profile
is based on the T-antigen structure [18]. Tn antigen was also detected by the binding lectin
VVL, which was also described in the basal membrane of the Teg and in the caeca of the adult
fluke [27]. Although the same author also described the presence of sialyl-Tn antigen in the
adult stage, we did not detect terminal sialic acid in the NEJTeg by MAL-II and SNA.
Taking into account the presence of these glycans in the oral and ventral suckers of the para-
site, we suggest that NEJ-derived glycoproteins decorated with terminal Man, Fuc and Gal/Gal-
NAc are in close contact with host mucins and intestinal enterocytes. Based on PNA positive
recognition at the parasite surface and around the suckers in F. hepatica, O-glycan motifs may
also play a role in intestinal epithelial invasion by this parasite, as has been shown also in stud-
ies of protozoal infections [60–63].
Differences in NEJTeg and NEJSom glycosylation were confirmed with four lectins. How-
ever, we also observed similar protein profiles in silver stained gels and in most of the lectin
blots. It is possible that some tegumental material remained in the somatic preparation or vice
versa. Due to the size of the NEJ and the relatively large number of parasites needed to obtain
enough material, it is very difficult to achieve a complete separation of NEJTeg and NEJSom. It
is known that some proteins are present in both F. hepatica Teg and Som. For example, the
protein PRX as well as paramyosin are found in both Teg and Som of adult F. hepatica [64–
66], although these studies also may be compromised by the difficulties encountered in achiev-
ing complete separation of the two fractions.
This is the first report that suggests that F. hepatica PRX and GST, which have well known
antioxidant and immunomodulatory properties [67–70], are glycoproteins. Particularly for
GST F. hepatica, it was not predicted to be potentially N-glycosylated, suggesting that it could
be O-glycosylated. The facts that (1) the F. hepatica NEJTeg O-glycan profile could not be con-
firmed in our previous analysis and (2) the O-glycan consensus is not as specific as that for N-
glycans limited our attempts to analyse potential O-glycosylation sites. It is reasonable to
assume that mucin-type core-1 O-glycan would be the most likely to be attached to the GST
due to the positive lectin binding of proteins at molecular weights of GST. Further studies will
be required to assess whether O-glycan structures are present and involved in the detoxification
and of immunoregulatory activities of these molecules.
To our knowledge, this is the first report describing the specific glycosylation of the F. hepat-
icaNEJ-specific cathepsin cysteine proteases. These molecules, which play an important role in
tissue degradation, in parasite penetration in the host gut and in parasite feeding [37,71] are
glycosylated by Manα1-3/6Manα1-4GlcNAcβ1-4GlcNAcβ1- N-glycan. Although there is some
evidence of the presence of Fuc on the chitobiose core, our analysis was inconclusive due to
restrictions on material. However, the presence of this glycan is shown in the PNG-F released
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glycan pool of NEJTeg. The confirmation of N-glycosylation of FhCL3 in our study differs
from previous findings [37,72]. Five genes were found in the F. hepatica genome encoding
FhCL3 [44], meaning that the proteins evaluated by previous workers and in the present study
could be different. Methodological differences may also be responsible. Previously, glycosyla-
tion of FhCL3 was assessed by detecting differences in protein migration in SDS-PAGE gel
after enzyme deglycosylation [37,72]. Because of the size and the mass of the N-glycan detected,
which is lower than 1 kDa, it is very difficult to measure differences in protein migration in
SDS-PAGE gels before and after deglycosylation. Therefore, this is not an accurate approach to
verify protein glycosylation when the glycans present are small. The use of MS for glycan analy-
sis is more sensitive and suitable for these purposes. The absence of N-glycosylation sites in
other trematode CL-like proteases [73], as well the presence of glycans in other various cathep-
sin proteinases including those from Trypanosoma brucei Cathepsin B [74] and human
Cathepsin V (also known as cathepsin L2) [75] has been reported.
Crucially, GST, PRX and FhCL3 have been proposed and used as potential vaccine candi-
dates. When these molecules were used as vaccines their maximum efficacy was observed when
antigens were used in their native, rather than recombinant, versions [11,15]. As the putative
glycans attached to GST and PRX have not been characterised we suggest that further in-depth
molecular glycomic analyses are necessary in order to prove the existence of N- and/or O- gly-
cosylation on these vaccine candidate molecules. There is only one report in the literature
where glycosylation of FhCL3 was taken into account for measuring vaccine efficacy. This
account involved rats vaccinated with recombinant FhCL3 expressed by Saccharomyces cerevi-
siae and recombinant baculovirus [76]. The formation of hyper high mannose-type N-glycans
by yeasts [77] and mammalian-like post-translational modifications by baculovirus vector
expression systems [78] differs significantly from the N-glycan structure identified for the
native FhCL3 in the present work. This could have an effect on the final protein folding and/or
the differences in the antigenic epitopes that could exist between the native protein and recom-
binant versions, explaining lack of efficacy of recombinant vaccine candidates. It is possible
that the presence of this unusual N-glycan attached to the FhCL3 peptide backbone is required
for proper processing and presentation. Correct glycosylation is an important issue for the pro-
duction of recombinant antigens of F. hepatica and other helminths [79]. Further work in
which alternative strategies for protein expression systems could be applied in order to express
cathepsins with their correct glycosylation profiles and again, ascertain their importance for
vaccine efficacy, is highly desirable.
In conclusion, we have demonstrated the presence of carbohydrates in the F. hepatica NEJ-
Teg and NEJSom, with differences in glycosylation between the two fractions. We also have
performed a glycan characterisation of the NEJTeg extract showing that high mannose and oli-
gomannose N-glycans are the most dominant glycan structures. Finally, this work has shown
that a set of important immunomodulatory proteins from F. hepatica NEJ, including some of
the cathepsin family clade, are glycosylated. Knowledge of the specific structures of the glycans
decorating these target proteins is particularly valuable for enhancing our understanding of
immunoevasion and parasite migration as well as optimising the efficacy of future vaccines.
Supporting Information
S1 Fig. Glycoprotein detection of F. hepatica NEJTeg and NEJSom by lectin blot. Both NEJ-
Teg (1) and NEJSom (2) preparations were SDS-PAGE fractioned, transferred to nitrocellulose
membranes and incubated with the biotinylated-labelled lectins UEA, SJA, VVL, STL, LEL,
DSL, SNA, MAL-II and RCA. An additional incubation with IRDye-labelled streptavidin was
used to detect positive lectin binding at different molecular weights (MW). Glycoproteins were
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revealed by infrared imaging.
(TIF)
S2 Fig. MALDI-TOF-MS spectra of AA-labelled N-linked glycans of F. hepatica NEJTeg
released using PNG-A. N-glycans released from NEJTeg using PNG-A were labelled with
fluorophore 2-aminobenzoic acid (2-AA). MS spectra of AA-labelled N-glycans were acquired
by MALDI-TOF-MS. Unidentified peaks are represented with an asterisk ().
(TIF)
S3 Fig. Confirmation of NEJ glycoprotein biotinylation and isolation. NEJTeg (1) was
employed for glycoprotein biotinylation. Biotinylated-NEJTeg (B-NEJTeg) (2) was used for
biotin-avidin affinity chromatography, separating avidin-unbound-NEJTeg (A-UB-NEJTeg
(3) and the avidin-bound-NEJTeg (A-BB-NEJTeg) (4) fractions. (A) SDS-PAGE and silver
staining was used to detect the protein profiles of the four preparations. (B) FITC labelled-
streptavidin-incubated membrane was used to confirm correct glycoprotein biotinylation of
B-NEJTeg and correct biotin-avidin affinity chromatography separation.
(TIF)
S1 File. Multiple sequence alignment of the F. hepatica NEJ cathepsins.Multiple sequence
alignment of FhCB (BN1106_s5100B000033), FhCB1 (BN1106_s6570B000050), FhCB2
(BN1106_s4482B000044) and FhCB3 (BN1106_s6570B000051) and ProCB2 (gi|27526823)
were performed using Clustal Omega. Sequences are ordered according to aligned. Differences
in the region containing the N-glycosylation site are highlighted in yellow. Consensus N-glyco-
sylation is underlined.
(PDF)
S1 Table. Comparison of the protein amino acid sequence of the FhCBs to gi|27526823.
(PDF)
S2 Table. Annotation of the additional glycopeptides identified in NEJTeg at bands 1, 2, 3
and 4 that did not correspond to the cathepsins.
(PDF)
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